At the 2026 ASCO Genitourinary Cancers Symposium, Dr. Andrea Necchi shared the final results of the SunRISe-2 phase 3 trial, ...

Introduction Maintaining normal fluid status is critical to health and well-being. Older people are vulnerable to abnormal fluid status and associated complications, morbidity and mortality. Care home ...

Inhaled seralutinib demonstrated clinical activity in high-risk pulmonary arterial hypertension patients despite missing its primary phase 3 endpoint.

Introduction Previous reviews have investigated the relationship between empathy and burnout. However, these are now out of date, did not capture the effect of the pandemic, did not include healthcare ...

In a subgroup analysis of people living with HIV enrolled in PRIOH-1, pritelivir demonstrated superior lesion healing, achieving 61% complete ...

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide further exploratory and post-hoc subgroup analysis data focusing on ...

Doctors say that identifying the right patients will be critical to the future of the field. Only time will tell, according to trialists.

First clinical development program in sporadic ALS patients to show potential to restore STATHMIN-2 expression, a statistically significant effect on a neurofilament biomarker, and an overall trend of ...

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma Delcath Systems, Inc.

Prophylactic treatment for hemophilia B necessitates lifelong, regular intravenous factor IX infusions. Gene therapy offers the possibility of a single-dose treatment that produces durable endogenous ...

New data in high-risk MDS, emerging menin inhibitors in AML, and evolving care needs in rare bleeding disorders set the stage for major ASH 2025 discussions. Ivo Carre, PhD, a senior business analyst ...

The MarketWatch News Department was not involved in the creation of this content. EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and ...